Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Dtsch Med Wochenschr ; 148(9): 519-527, 2023 04.
Article in German | MEDLINE | ID: mdl-37094587

ABSTRACT

Factors related to patient diversity may play a major role in the pathogenesis and clinical manifestation of intestinal and liver diseases and should be considered during diagnostic workup and therapeutic decisions. Here we discuss how diversity factors such as gender, ethnicity, age and socioeconomic parameters may affect the manifestation and disease course of inflammatory bowel diseases (IBD, i.e. Crohn's disease and ulcerative colitis). Consideration of such factors may help to pave the path towards personalized medicine approaches in clinical practice.


Subject(s)
Colitis, Ulcerative , Crohn Disease , Gastroenterology , Inflammatory Bowel Diseases , Humans , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/therapy , Colitis, Ulcerative/therapy , Crohn Disease/therapy
2.
Dtsch Med Wochenschr ; 146(3): 193-197, 2021 02.
Article in German | MEDLINE | ID: mdl-33513656

ABSTRACT

INTRODUCTION: Postinfantile giant cell hepatitis is a rare entity in adult hepatopathy caused by various etiologies that can be summarized by their characteristic giant cells in histopathologic examination. Frequently, association with autoimmune, infectious and hepatotoxic events is described. Therefore, therapy consists in treatment of underlying diseases and immunosuppression. HISTORY: We saw an 76-year-old patient due to histologically proven Postinfantile giant cell hepatitis. Despite administering budesonid as an initial attempt of treatment, no improvement in hepatitis was achieved. Hence, the patient was forwarded to us. FINDINGS: Neither regarding the patient's history nor in laboratory and serological tests, nor in histopathological analysis of liver biopsies an underlying cause of giant cell hepatitis was identified. THERAPY AND COURSE: Despite immunosuppressive therapy with glucocorticoids alone, cyclophosphamide and a monoclonal anti-CD20-antibody, giant cell hepatitis was not controlled. Hence, we started treatment with the calcineurin inhibitor Tacrolimus combined with low-dose prednisolone and thus were able to lower patient's liver values and stabilize hepatitis. CONCLUSION: The good effectiveness of tacrolimus in our patient underlines the important role of calcineurin inhibitors in treating Postinfantile giant cell hepatitis, although rarely reported to date.


Subject(s)
Calcineurin Inhibitors/therapeutic use , Hemochromatosis , Aged , Female , Hemochromatosis/diagnosis , Hemochromatosis/drug therapy , Hemochromatosis/pathology , Humans , Liver/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...